Home / Products / Genome-edited Cells / FSBP Knockout Raji Polyclonal Cells

FSBP Knockout Raji Polyclonal Cells

Cat. No. ARG0879
Product Type:

Polyclonal Cell Population

Species:

Homo sapiens (Human)

Tissue Source:

Bone

Growth Properties:

Suspension

In stock
Request a Quote
Ask a Question

Short Description 🔒

The FSBP Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Raji B lymphocytes, designed for loss-of-function studies of the FSBP (FOXP4) transcription factor. This model targets a transcriptional repressor involved in Wnt/beta-catenin and TGF-beta/Smad pathways, interacting with CTBP1, HDAC1, and SMAD3, and regulating downstream targets such as FGG and CDH1. Applicable to B-cell malignancy research, gene function analysis, and drug target validation, this polyclonal knockout enables assays including western blotting, RT-qPCR, and cell proliferation studies. The Raji background provides a robust EBV-positive Burkitt lymphoma model for investigating FSBP-mediated mechanisms in lymphomagenesis and signaling.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Bone
Disease:
Burkitt lymphoma
Cell Type:
B cell line
Morphology:
Lymphoblast-like
Growth Mode:
Suspension
Age:
11 years
Sex of Donor:
Male
Derived From Site:
In situ; Maxilla
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice
Storage:
Liquid nitrogen (LN2)

Cell Engineering Information

Host Cell:
Raji
Gene Name:
FSBP
Gene Identifier:
NCBI Gene ID 100861412

Immortalization Information

No immortalization information available.

Culture Conditions

Growth medium:
RPMI 1640
Supplement(s):
10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution
Temperature:
37°C
Atmosphere:
5% CO?

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up‑to‑date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description 🔒

The FSBP Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, designed to introduce loss-of-function of the FSBP (FOXP4) gene. This polyclonal model enables functional studies of FSBP-mediated transcriptional repression without clonal selection bias, providing a heterogeneous knockout background for evaluating gene disruption effects on B-cell biology.

The Raji cell line, established from a Burkitt lymphoma patient, is an Epstein-Barr virus (EBV)-positive B lymphocyte model widely used in hematological malignancy research. These cells exhibit characteristics of mature B cells and retain key signaling pathways relevant to lymphomagenesis, including constitutive activation of survival and proliferation signals. The Raji background is particularly suited for investigating B-cell receptor signaling, EBV-mediated oncogenesis, and apoptotic regulation, making it a valuable platform for dissecting gene function in B-cell malignancies.

FSBP, encoded by the FOXP4 gene, is a forkhead box transcription factor that functions as a transcriptional repressor, regulating genes involved in epithelial-mesenchymal transition (EMT), cell cycle progression, and fibrinogen expression. Mechanistically, FSBP interacts with corepressors such as CTBP1, HDAC1, and SMAD3, and represses downstream targets including FGG, CDH1 (E-cadherin), and VIM (vimentin), while modulating CCND1 (cyclin D1) and MMP2. Its activity is regulated by upstream signals like TGF-beta1, Wnt3a, ERK, and PI3K/AKT pathways, integrating into broader Wnt/beta-catenin and TGF-beta/Smad signaling networks through beta-catenin, TCF/LEF transcription factors, and SMAD2/3 complexes. This positions FSBP at the intersection of developmental signaling and cancer-related pathways, where it influences cell fate decisions.

In the Raji B lymphocyte context, FSBP knockout provides a model to interrogate how this transcription factor contributes to B-cell survival, proliferation, and transformation. Given that Raji cells display activated Wnt/beta-catenin and TGF-beta signaling, FSBP disruption may alter the balance of proliferative and apoptotic signals, potentially impacting pathways mediated by AKT, ERK, and beta-catenin. This model is particularly relevant for studying the molecular mechanisms underlying Burkitt lymphoma pathogenesis, as FSBP may modulate gene expression programs that sustain the malignant phenotype, including those influenced by EBV latency factors.

Researchers can employ this knockout polyclonal population in a broad range of assays, such as western blotting and RT-qPCR to assess changes in downstream targets like FGG and CDH1, flow cytometry for phenotyping B-cell surface markers, cell proliferation and apoptosis assays for functional endpoints, and co-immunoprecipitation to map FSBP interactomes. The model supports studies in gene function analysis, B-cell malignancy research, drug target validation, and signaling pathway dissection (e.g., Wnt/beta-catenin and TGF-beta/Smad). For additional technical information, including availability, licensing, and custom orders, please contact Ascent Research.